Browsing by Author "Lerner, Seth Paul"

Sort by: Order: Results:

  • Lerner, Seth Paul; McConkey, David; Hoadley, Katherine A.; Chan, Keith S.; Kim, William Y.; Radvanyi, François; Höglund, Mattias; Real, Francisco X. (IOS Press, 2016)
    The advent of Omics technologies has been key to the molecular subclassification of urothelial bladder cancer. Several groups have used different strategies to this aim, with partially overlapping findings. The meeting at ...
  • Choi, Woonyoung; Ochoa, Andrea; McConkey, David; Aine, Mattias; Höglund, Mattias; Kim, William Y.; Real, Francisco X.; Kiltie, Anne E.; Milsom, Ian; Dyrskjøt, Lars; Lerner, Seth Paul (Elsevier, 2017)
    CONTEXT: Recent whole genome mRNA expression profiling studies revealed that bladder cancers can be grouped into molecular subtypes, some of which share clinical properties and gene expression patterns with the intrinsic ...
  • Pal, Sumanta; Somford, Diederik M.; Grivas, Petros; Sridhar, Srikala S.; Gupta, Shilpa; Bellmunt Molins, Joaquim, 1959-; Sonpavde, Guru; Fleming, Mark T.; Lerner, Seth Paul; Loriot, Yohann; Hoffman-Censits, Jean; Valderrama, Begoña P.; Andresen, Corina; Schnabel, Marco J.; Cole, Suzanne; Daneshmand, Siamak (Future Medicine, 2022)
    PROOF 302 is an ongoing randomized, double-blind, placebo-controlled, adjuvant phase III trial (NCT04197986) in approximately 218 patients from 120 centers worldwide. Eligibility criteria include post-surgical high-risk ...

Search DSpace


My Account

In collaboration with Compliant to Partaking